Abstract
Abstract: Nivolumab was registered in Russia in December 2016 as a monotherapy for advanced renal cell carcinoma (RCC) and it remains a second‑line treatment choice for patients with disease progression after the use of tyrosine kinase inhibitors. Even though immunotherapy has already proven to be an effective approach for the treatment of RCC, predictive biomarkers for the rational selection of patients remain unidentified.Seventy‑five patients with metastatic renal cell carcinoma (mRCC) who received nivolumab in the 2nd and subsequent lines of therapy from 2015 to 2020 under the expanded access program were enrolled in this study. The objective response rate was 21,3 %. Median progression‑free survival (PFS) was 5,5 months. Median overall survival (OS) was not reached.To analyze molecular biomarkers correlated with the response to immunotherapeutic treatment, we performed whole‑transcriptome RNA sequencing of 16 samples (FFPE) in 15 patients with the assessment of the expression level for individual genes (PDCD1, CD274, CD8A, CD8B, CD4) and gene signatures (Angio, Teff, Myeloid Inflammation).Disease control rates were not different for the subgroups of patients with high and low expression of any of the signatures examined, and further principal component analysis did not reveal clustering of patients with and without objective response.Further studies on a larger sample of patients will help confirm or deny the predictive role of biomarkers selected for analysis in a heterogeneous population of RCC patients.
Highlights
Концентрацию ДНК измеряли флуориметри‐ ческим методом с использованием набора Qubit DNA BR assay kit (Thermo Fisher) на приборе Qubit-2 (Thermo Fisher) в соответствии с протоколом от производителя
Nivolumab was registered in Russia in December 2016 as a monotherapy for advanced renal cell carcinoma (RCC) and it remains a second-line treatment choice for patients with disease progression after the use of tyrosine ki‐ nase inhibitors
Even though immunotherapy has already proven to be an effective approach for the treatment of RCC, predictive biomarkers for the rational selection of patients remain unidentified
Summary
Опыт применения ниволумаба у российских пациентов с метастатическим почечно-клеточным раком в рамках программы расширенного доступа. Аннотация: В России ниволумаб был зарегистрирован в декабре 2016 года в качестве монотерапии распространенного почечно-клеточного рака (ПКР) и до сих пор остается препаратом выбора при проведении терапии второй линии у пациентов с прогрессированием процесса после использования тирозинкиназных ингибиторов. В данное исследование было включено 75 пациентов с метастатическим почечно-клеточным раком (мПКР), получивших ниволумаб во 2‐й и последующих линиях терапии с 2015 по 2020 года в рамках программы расширенного доступа к препарату. Частота контроля заболевания не отличалась в подгруппах пациентов с высоким и низким значением экспрессии какой‐либо из исследованных сигнатур, а дальнейший анализ методом главных компонент не позволил выявить кластеризацию пациентов с наличием и отсутствием объективного ответа. ЗЛОКАЧЕСТВЕННЫЕ ОПУХОЛИ Российское общество клинической онкологии том / vol 11 No 3 2021
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.